Amphetamine and 2-phenylethylamine in post-mortem Parkinsonian brain after (-)deprenyl administration. 1978

G P Reynolds, and P Riederer, and M Sandler, and K Jellinger, and D Seemann

Deprenyl is an inhibitor of monoamine oxidase type B, the enzyme responsible for 2-phenylethylamine oxidation, and is used in conjunction with L-Dopa therapy in Parkinson's disease. Post-mortem studies in human brain tissue have shown that after (-)deprenyl administration to parkinsonian patients amphetamine is present in concentrations up to 56 ng/g. It also could be shown that phenylethylamine concentrations are substantially increased in such patients. Phenylethylamine and amphetamine have been investigated using a gas chromatographic technique.

UI MeSH Term Description Entries
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D010627 Phenethylamines A group of compounds that are derivatives of beta- aminoethylbenzene which is structurally and pharmacologically related to amphetamine. (From Merck Index, 11th ed) Phenylethylamines
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000662 Amphetamines Analogs or derivatives of AMPHETAMINE. Many are sympathomimetics and central nervous system stimulators causing excitation, vasopressin, bronchodilation, and to varying degrees, anorexia, analepsis, nasal decongestion, and some smooth muscle relaxation.
D012642 Selegiline A selective, irreversible inhibitor of Type B monoamine oxidase that is used for the treatment of newly diagnosed patients with PARKINSON DISEASE, and for the treatment of depressive disorders. The compound without isomeric designation is Deprenyl. Deprenalin,Deprenil,Deprenyl,E-250,Eldepryl,Emsam,Humex,Jumex,L-Deprenyl,Selegiline Hydrochloride,Selegiline Hydrochloride, (R)-Isomer,Selegiline Hydrochloride, (R,S)-Isomer,Selegiline Hydrochloride, (S)-Isomer,Selegiline, (R)-Isomer,Selegiline, (R,S)-Isomer,Selegiline, (S)-Isomer,Selegyline,Yumex,Zelapar,E 250,E250

Related Publications

G P Reynolds, and P Riederer, and M Sandler, and K Jellinger, and D Seemann
November 1981, The Journal of pharmacy and pharmacology,
G P Reynolds, and P Riederer, and M Sandler, and K Jellinger, and D Seemann
June 1984, Brain research,
G P Reynolds, and P Riederer, and M Sandler, and K Jellinger, and D Seemann
October 1996, Neurochemical research,
G P Reynolds, and P Riederer, and M Sandler, and K Jellinger, and D Seemann
November 1974, Life sciences,
G P Reynolds, and P Riederer, and M Sandler, and K Jellinger, and D Seemann
August 1960, Experientia,
G P Reynolds, and P Riederer, and M Sandler, and K Jellinger, and D Seemann
January 1986, Archives internationales de pharmacodynamie et de therapie,
G P Reynolds, and P Riederer, and M Sandler, and K Jellinger, and D Seemann
July 2022, Medical science monitor : international medical journal of experimental and clinical research,
G P Reynolds, and P Riederer, and M Sandler, and K Jellinger, and D Seemann
January 1984, Progress in neuro-psychopharmacology & biological psychiatry,
G P Reynolds, and P Riederer, and M Sandler, and K Jellinger, and D Seemann
October 1975, Life sciences,
G P Reynolds, and P Riederer, and M Sandler, and K Jellinger, and D Seemann
March 1980, Brain research,
Copied contents to your clipboard!